{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:43:19Z","timestamp":1789699399445,"version":"4.0.1"},"reference-count":38,"publisher":"American Psychiatric Association Publishing","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AJP"],"published-print":{"date-parts":[[1999,5,1]]},"DOI":"10.1176\/ajp.156.5.702","type":"journal-article","created":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T16:19:01Z","timestamp":1659111541000},"page":"702-709","source":"Crossref","is-referenced-by-count":433,"title":["Olanzapine Versus Placebo in the Treatment of Acute Mania"],"prefix":"10.1176","volume":"156","author":[{"given":"Mauricio","family":"Tohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M.","family":"Sanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"McElroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary D.","family":"Tollefson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.N. Roy","family":"Chengappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Petty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franca","family":"Centorrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Starr L.","family":"Grundy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Greaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy R.","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verna","family":"Toma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"The Olanzapine HGEH Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"230","reference":[{"key":"R1565BABHIHIE","doi-asserted-by":"crossref","unstructured":"Regier DA, Myers JK, Kramer M, Robins LN, Blazer DG, Hough RL, Eaton WW, Locke BZ: The NIMH Epidemiologic Catchment Area Program: historical context, major objectives, and study population characteristics. Arch Gen Psychiatry 1984; 41:934\u2013941","DOI":"10.1001\/archpsyc.1984.01790210016003"},{"key":"atypb1","doi-asserted-by":"crossref","unstructured":"Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen H-U, Kendler KS: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:8\u201319","DOI":"10.1001\/archpsyc.1994.03950010008002"},{"key":"atypb3","doi-asserted-by":"crossref","unstructured":"Post RM, Uhde TW, Roy-Byrne PP, Joffe RT: Correlates of antimanic response to carbamazepine. Psychiatry Res 1987; 21:71\u201383","DOI":"10.1016\/0165-1781(87)90064-3"},{"key":"R1565BABEIIGG","unstructured":"Zarate CA Jr, Tohen M, Baldessarini RJ: Clozapine in severe mood disorders. J Clin Psychiatry 1995; 56:411\u2013417"},{"key":"atypb4","doi-asserted-by":"crossref","unstructured":"Calabrese JR, Kimmel SE, Woyshville MJ, Rapport DJ, Faust CJ, Thompson PA, Meltzer HY: Clozapine for treatment-refractory mania. Am J Psychiatry 1996; 153:759\u2013764","DOI":"10.1176\/ajp.153.6.759"},{"key":"atypb5","doi-asserted-by":"crossref","unstructured":"Frye MA, Ketter TA, Altshuler LL, Denicoff K, Dunn RT, Kimbrell TA, Cora-Locatelli G, Post RM: Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics. J Affect Disord 1998; 48:91\u2013104","DOI":"10.1016\/S0165-0327(97)00160-2"},{"key":"atypb6","doi-asserted-by":"crossref","unstructured":"Suppes T, Rush AJ, Webb A, Carmody T, Kraemer H: A one-year randomized trial of clozapine vs usual care in bipolar I patients (abstract). Biol Psychiatry 1996; 39:531","DOI":"10.1016\/0006-3223(96)84056-X"},{"key":"R1565BABDABGD","unstructured":"Zarate CA Jr, Tohen M, Banov MD, Weiss MK, Cole JO: Is clozapine a mood stabilizer? J Clin Psychiatry 1995; 56:108\u2013112"},{"key":"R1565BABJBFFH","doi-asserted-by":"crossref","unstructured":"Baldessarini RJ, Frankenburg FR: Clozapine: a novel antipsychotic agent. N Engl J Med 1991; 324:746\u2013754","DOI":"10.1056\/NEJM199103143241107"},{"key":"R1565BABHBDFA","unstructured":"Tohen M, Zarate CAJ, Centorrino F, Hegarty JI, Froeschl M, Zarate SB: Risperidone in the treatment of mania. J Clin Psychiatry 1996; 57:249\u2013253"},{"key":"R1565BABEJIBA","unstructured":"Keck PEJ, Wilson DR, Strakowski SM, McElroy SL, Kizer DL, Balistreri TM, Holtman HM, DePriest M: Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. J Clin Psychiatry 1995; 56:466\u2013470"},{"key":"R1565BABGCAJJ","unstructured":"Moore NA, Calligaro DC, Wong DT, Bymaster FP, Tye NC: The pharmacology of olanzapine and other new antipsychotic agents. Current Opinions in Investigational Drugs 1993; 2:281\u2013293"},{"key":"R1565BABCBBJD","doi-asserted-by":"crossref","unstructured":"Tollefson GD, Sanger TM, Lu MK, Thieme ME: Depressive signs and symptoms in schizophrenia\u2014a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998; 55:250\u2013258","DOI":"10.1001\/archpsyc.55.3.250"},{"key":"atypb7","doi-asserted-by":"crossref","unstructured":"Beasley CM Jr, Hamilton S, Crawford AM, Dellva M, Tollefson GD, Tran PV, Beuzen J, Olanzapine E003 Study Group: Olanzapine versus haloperidol: acute-phase results of the International double-blind olanzapine trial. Eur Neuropsychopharmacol 1997; 7:125\u2013137","DOI":"10.1016\/S0924-977X(96)00392-6"},{"key":"atypb8","doi-asserted-by":"crossref","unstructured":"Beasley CM Jr, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S: Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996; 124:159\u2013167","DOI":"10.1007\/BF02245617"},{"key":"atypb9","doi-asserted-by":"crossref","unstructured":"Hamilton SH, Revicki DA, Genduso LA, Beasley CM Jr: Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology 1997; 18:41\u201349","DOI":"10.1016\/S0893-133X(97)00111-5"},{"key":"R1565BABFEEAA","doi-asserted-by":"crossref","unstructured":"Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154:457\u2013465","DOI":"10.1176\/ajp.154.4.457"},{"key":"R1565BABFCIHE","doi-asserted-by":"crossref","unstructured":"Beasley CM Jr, Tollefson G, Tran PV, Satterlee W, Sanger T, Hamilton S, Olanzapine HGAD Study Group: Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14:111\u2013123","DOI":"10.1016\/0893-133X(95)00069-P"},{"key":"R1565BABBHJDD","doi-asserted-by":"crossref","unstructured":"Zarate CJ, Narendran R, Tohen M, Greaney J, Berman A, Pike S, Madrid A: Clinical predictors of acute response with olanzapine in psychotic mood disorders. J Clin Psychiatry 1998; 59:24\u201328","DOI":"10.4088\/JCP.v59n0106"},{"key":"atypb10","doi-asserted-by":"crossref","unstructured":"McElroy SL, Frye MA, Denikoff KD, Altshuler LL, Nolen W, Kupka R, Suppes T, Keck PE, Leverich GS, Kmetz GF, Post PM: Olanzapine in treatment-resistant bipolar disorder. J Affect Disord 1998; 49:119\u2013122","DOI":"10.1016\/S0165-0327(98)00002-0"},{"key":"R1565BABJGICD","unstructured":"Ravindran AV, Jones BW, Al-Zaid K, Lapierre YD: Effective treatment of mania with olanzapine:2 case reports. J Psychiatry Neurosci 1997; 22:345\u2013346"},{"key":"R1565BABEHDDI","doi-asserted-by":"crossref","unstructured":"Spitzer RL, Williams JBW, Gibbon M, First MB: The Structured Clinical Interview for DSM-III-R (SCID), I: history, rationale, and description. Arch Gen Psychiatry 1992; 49:624\u2013629","DOI":"10.1001\/archpsyc.1992.01820080032005"},{"key":"R1565BABJJBGI","doi-asserted-by":"crossref","unstructured":"Young RC, Biggs JT, Ziegler VE, Meyer DA: A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133:429\u2013435","DOI":"10.1192\/bjp.133.5.429"},{"key":"R1565BABHBGJE","doi-asserted-by":"crossref","unstructured":"Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6:278\u2013296","DOI":"10.1111\/j.2044-8260.1967.tb00530.x"},{"key":"R1565BABEAJAG","doi-asserted-by":"crossref","unstructured":"Spearing MK, Post PM, Leverich GS, Brandt D, Nolen W: Modification of the Clinical Global Impression (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatr Res 1997; 73:159\u2013171","DOI":"10.1016\/S0165-1781(97)00123-6"},{"key":"R1565BABGJFEF","doi-asserted-by":"crossref","unstructured":"Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Act Psychiatr Scand Suppl 1970; 212:11\u201319","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"},{"key":"R1565BABFFIIE","doi-asserted-by":"crossref","unstructured":"Barnes TR: A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672\u2013676","DOI":"10.1192\/bjp.154.5.672"},{"key":"R1565BABDEGFH","doi-asserted-by":"crossref","unstructured":"Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Dilsaver SC, David JM, Rush AJ, Small JG, Garza-Trevino ES, Risch C, Goodnick PJ, Morris DD: Efficacy of divalproex versus lithium and placebo in the treatment of mania. JAMA 1994; 271:918\u2013924","DOI":"10.1001\/jama.271.12.918"},{"key":"R1565BABIIGAE","doi-asserted-by":"crossref","unstructured":"Pope HGJ, McElroy SL, Keck PE, Hudson JI: Valproate in the treatment of acute mania: a placebo-controlled study. Arch Gen Psychiatry 1991; 48:62\u201368","DOI":"10.1001\/archpsyc.1991.01810250064008"},{"key":"R1565BABEEBDF","doi-asserted-by":"crossref","unstructured":"Kukopulos A, Reginaldi D, Laddomada P, Floris G, Serra G, Tondo L: Course of the manic depressive cycle and changes caused by treatment. Pharmacopsychiatria 1980; 13:156\u2013167","DOI":"10.1055\/s-2007-1019628"},{"key":"R1565BABCBGFB","doi-asserted-by":"crossref","unstructured":"White E, Cheung P, Silverstone T: Depot antipsychotics in bipolar affective disorder. Int Clin Psychopharmacol 1993; 8:119\u2013122","DOI":"10.1097\/00004850-199300820-00007"},{"key":"atypb11","doi-asserted-by":"crossref","unstructured":"Ahlfors UG, Baastrup PC, Dencker SJ, Elgen K, Lingjaerde O, Pedersen V, Schou M, Aaskoven O: Flupenthixol decanoate in recurrent manic-depressive illness. Acta Psychiatr Scand 1981; 64:226\u2013237","DOI":"10.1111\/j.1600-0447.1981.tb00778.x"},{"key":"atypb12","doi-asserted-by":"crossref","unstructured":"Morgan HG: The incidence of depressive symptoms during recovery from hypomania. Br J Psychiatry 1972; 120:537\u2013539","DOI":"10.1192\/bjp.120.558.537"},{"key":"R1565BABEADID","doi-asserted-by":"crossref","unstructured":"Kane JM, Woerner M, Weinhold P, Wegner J, Kinon B: A prospective study of tardive dyskinesia development: preliminary results. J Clin Psychopharmacol 1982; 2:345\u2013349","DOI":"10.1097\/00004714-198210000-00012"},{"key":"R1565BABCHAGI","doi-asserted-by":"crossref","unstructured":"Tran PV, Dellva MA, Tollefson GD, Beasley CM Jr, Potvin JH, Kiesler GM: Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 1997; 58:205\u2013211","DOI":"10.4088\/JCP.v58n0505"},{"key":"R1565BABDDICH","doi-asserted-by":"crossref","unstructured":"Tollefson GD, Beasley CM Jr, Tamura RN, Tran PV, Potvin JH: A blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997; 154:1248\u20131254","DOI":"10.1176\/ajp.154.9.1248"},{"key":"R1565BABCCGFA","unstructured":"Janicak PG, Sharma RP, Easton M, Cornat JE, Davis JM: A double-blind, placebo-controlled trial of clonidine in the treatment of acute mania. Psychopharmacol Bull 1989; 25:243\u2013245"},{"key":"R1565BABFIIFD","unstructured":"Lenox RH, Newhouse PA, Creelman WL, Whitaker TM: Adjunctive treatment of manic agitation with lorazepam versus haloperidol: a double-blind study. J Clin Psychiatry 1992; 53:47\u201352"}],"container-title":["American Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ajp.psychiatryonline.org\/doi\/10.1176\/ajp.156.5.702","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T16:13:40Z","timestamp":1721837620000},"score":1,"resource":{"primary":{"URL":"https:\/\/psychiatryonline.org\/doi\/10.1176\/ajp.156.5.702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,5,1]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1999,5,1]]}},"alternative-id":["10.1176\/ajp.156.5.702"],"URL":"https:\/\/doi.org\/10.1176\/ajp.156.5.702","relation":{},"ISSN":["0002-953X","1535-7228"],"issn-type":[{"value":"0002-953X","type":"print"},{"value":"1535-7228","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,5,1]]}}}